Cargando…
17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF(V600E) inhibitors in melanoma cells of different genetic subtypes
Outcomes of melanoma patient treatment remain unsatisfactory despite accessibility of oncoprotein-targeting drugs and immunotherapy. Here, we reported that 17-aminogeldanamycin more potently activated caspase-3/7 in BRAF(V600E) melanoma cells than geldanamycin, another inhibitor of heat shock protei...
Autores principales: | Mielczarek-Lewandowska, Aleksandra, Sztiller-Sikorska, Malgorzata, Osrodek, Marta, Czyz, Malgorzata, Hartman, Mariusz L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598962/ https://www.ncbi.nlm.nih.gov/pubmed/30989459 http://dx.doi.org/10.1007/s10495-019-01542-y |
Ejemplares similares
-
Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of (V600E)BRAF melanoma cells and their response to vemurafenib and trametinib in vitro
por: Zalesna, Izabela, et al.
Publicado: (2017) -
17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines
por: Hartman, Mariusz L., et al.
Publicado: (2020) -
Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
por: Hartman, Mariusz L., et al.
Publicado: (2020) -
Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
por: Czyz, Malgorzata, et al.
Publicado: (2019) -
TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF(V600E) melanoma cells
por: Hartman, Mariusz L., et al.
Publicado: (2019)